Jordan R. Stern

Jordan R. Stern

Auto-generated profile, based on publicly available information

Jordan R. Stern

Weill Cornell Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Journal of Cardiovascular Surgery
Verified
Journal Article
Closed access
AFArash Fereydooni
Arash Fereydooni
JSJordan R. Stern
Jordan R. Stern
Article: Contemporary treatment of May-Thurner Syndrome - The Journal of Cardiovascular Surgery 2021 October;62(5):447-55 - Minerva Medica - Journals

20 April 2022 in Seminars in Vascular Surgery
Verified
Journal Article
Closed access
MPMichael J. Paisley
Michael J. Paisley
SAShaunak Adkar
Shaunak Adkar
BSBrian M. Sheehan
Brian M. Sheehan
JSJordan R. Stern
Jordan R. Stern

1 January 2021 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
VHVy T. Ho
Vy T. Ho
NINathan K. Itoga
Nathan K. Itoga
KTKenneth Tran
Kenneth Tran
JLJason T. Lee
Jason T. Lee
JSJordan R. Stern
Jordan R. Stern
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) is indicated for treatment of aneurysms, dissections, and traumatic injury. We describe mid-term mortality and reintervention rates in Medicare beneficiaries undergoing TEVAR. STUDY DESIGN: Patients who underwent TEVAR between 2006 and 2014 were identified by CPT codes in a 20% Medicare sample. Indication for aortic repair (aneurysm, dissection, trauma) was ascertained via ICD-9 codes. Follow-up was evaluated until 2015. Kaplan-Meier survival analysis and Cox regression were used to compare mortality, with reintervention and mortality rates expressed as a composite outcome in a hazard ratio with 95% confidence interval (hazard ratio [HR] 95% CI). RESULTS: There were 3,095 patients who underwent TEVAR during the study period: 1,465 (47%) for aneurysm, 1,448 (47%) for dissection, and 182 (5.9%) for trauma. Mean patient age was 74.4 years, and 44.5% were female. Median follow-up was 2.7 years. The overall 30-day, 1-year, and 5-year, and 8-year survival rates were 93%, 78%, 49%, and 33%, respectively. Thirty-day mortality was highest in traumatic indications, but overall mortality was highest in patients undergoing TEVAR for aneurysm. Freedom from combined reintervention and mortality at 30 days, 1 year, 5 years, and 8 years was 89%, 73%, 43%, and 29%, respectively. Reintervention was highest in patients undergoing TEVAR for dissection (12.8%), followed by aneurysm (10.0%) and trauma (5.5%). Advanced age (HR 1.03 per year, 95% CI 1.02–1.03), congestive heart failure (CHF) (HR 1.48, 95% CI 1.33–1.65), dementia (HR 1.40, 95% CI 1.14–1.28), and rupture (HR 1.38, 95% CI 1.24–1.54) were associated with mortality. CONCLUSIONS: Midterm survival is lower in patients who undergo TEVAR for dissection and aneurysm compared with trauma. Aneurysmal disease, advanced age, CHF, dementia, and aortic rupture are associated with mortality and reintervention in TEVAR.

1 January 2019 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
JSJordan R. Stern
Jordan R. Stern
TSTianyi Sun
Tianyi Sun
JMJialin Mao
Jialin Mao
ASArt Sedrakyan
Art Sedrakyan
AMAndrew J. Meltzer
Andrew J. Meltzer

1 October 2021 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
JSJordan R. Stern
Jordan R. Stern
KTKenneth Tran
Kenneth Tran
MLMing Li
Ming Li
JLJason T. Lee
Jason T. Lee

1 April 2018 in The Journal of Cardiovascular Surgery
Verified
Journal Article
Closed access
KLKedar S. Lavingia
Kedar S. Lavingia
ADAnahita Dua
Anahita Dua
JSJordan R. Stern
Jordan R. Stern
Article: Upper extremity access options for complex endovascular aortic interventions - The Journal of Cardiovascular Surgery 2018 June;59(3):360-7 - Minerva Medica - Journals